Holen Sie sich die Stockscreener-App
14.18
30.21%
3.29
Handel nachbörslich:
14.16
-0.02
-0.14%
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025) - ts2.tech
Top Biotech Stocks To Add to Your WatchlistDecember 20th - MarketBeat
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare disease company with a presence in Philadelphia - MSN
Amicus Therapeutics Stock Surges Post-BioMarin Acquisition Announcement - StocksToTrade
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion - MSN
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion - ts2.tech
After shakeup under new CEO, drugmaker BioMarin turns its cash on a big deal - The Business Journals
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger - Finviz
Amicus Therapeutics Sees Stock Surge Amid BioMarin Acquisition Deal - timothysykes.com
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025) - ts2.tech
Assenagon Asset Management S.A. Lowers Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to buy Amicus Therapeutics for $4.8 billion - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion By Investing.com - Investing.com South Africa
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open - ts2.tech
Amicus Therapeutics Inc. (FOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
San Rafael’s BioMarin Drops $4.8 Billion Bet On Rare-Disease Rival - Hoodline
Health Care Up Amid Deal Activity -- Health Care Roundup - MarketWatch
BioMarin, Amicus Agree To $4.8bn Buyout, Combining Rare Disease Portfolios - Citeline News & Insights
Officer Clark Files To Sell 25,642 Of Amicus Therapeutics Inc [FOLD] - TradingView — Track All Markets
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy - BioWorld MedTech
BioMarin Stock Jumps After Nearly $5 Billion Amicus Therapeutics Deal - Barron's
BioMarin to expand portfolio with $4.8B buy of Amicus - The Pharma Letter
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News
Amicus Therapeutics: A Surge Worth Noticing? - StocksToTrade
Promising Biotech Stocks To Follow NowDecember 19th - MarketBeat
BioMarin to acquire Amicus Therapeutics for $4.8B - Axios
BioMarin soars 20% after folding in the $4.8 billion takeover of Amicus - MSN
Amicus Therapeutics (FOLD) Surges Over 30% Amid Positive Market Activity - GuruFocus
Shareholder Alert: The Ademi Firm investigates whether Amicus Th - GuruFocus
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics - PharmExec.com
BioMarin is buying Amicus Therapeutics for $4.8 billion - Inquirer.com
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday - Benzinga
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion - wsj.com
BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved - Law360
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpTime to Buy? - MarketBeat
Amicus Therapeutics (FOLD) Downgraded by Needham to 'Hold' | FOL - GuruFocus
BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus - Fierce Pharma
Needham & Company LLC Reaffirms "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Kirkland Advises Amicus Therapeutics on $4.8 Billion Sale to BioMarin - Kirkland & Ellis LLP
Amicus Therapeutics (FOLD) Downgraded by Cantor Fitzgerald | FOL - GuruFocus
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet - MSN
BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics, Inc. for $4.7 billion. - marketscreener.com
Amicus Therapeutics (NASDAQ:FOLD) Receives Neutral Rating from Cantor Fitzgerald - MarketBeat
Amicus Therapeutics (FOLD) Shares Surge Over 30% - GuruFocus
BioMarin Pharmaceutical to Acquire Amicus Therapeutics in $4.8 Billion Deal - marketscreener.com
BioMarin buys pharma peer Amicus for $4.8bn - Sharecast.com
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio - ts2.tech
BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump - marketscreener.com
BioMarin to Buy Amicus in $4.8 Billion Bet on Rare Disease Drugs - Bloomberg.com
Market news - investments.halifax.co.uk
Amicus Therapeutics to Be Acquired by BioMarin - TipRanks
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Amicus Therapeutics Signs Agreement and Plan of Merger With BioMarin Pharmaceutical - TradingView — Track All Markets
BioMarin to acquire Amicus in all-cash deal with equity value of $4.8 bn - MLex
BioMarin to Acquire Amicus, Expanding Rare Disease Portfolio - TipRanks
Amicus Therapeutics: Soaring on Analyst’s Optimism? - timothysykes.com
BioMarin to Buy Amicus Therapeutics for $4.8 Billion - The Wall Street Journal
BioMarin To Acquire Amicus Therapeutics For $4.8 Billion - citybiz
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):